BioLife Sciences Overview
BioLife Sciences (BLFE) has a ROE of 319716.51%, above the sector sector average of 11.75%.
Get informed when a big investor buys or sells
+ Follow319716.51%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
BioLife Sciences (BLFE) currently reports a ROE of 319716.51%. That is above the sector sector average of 11.75%. Use the charts on this page to explore BioLife Sciences's ROE history and peer comparisons.
BioLife Sciences's ROE of 319716.51% is higher than the its sector sector average of 11.75%. That is roughly 2719927.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but BioLife Sciences's current 319716.51% should be judged against industry norms (sector average: 11.75%) and against BLFE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 319716.51%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.75%. From there, open related valuation or income-statement pages for BioLife Sciences, and consider following BLFE for alerts when major investors trade the stock.
